guest ::
| Home > Publications Database > 7T MRS Glutamate and GABA in Alzheimer’s Disease > print |
| 001 | 283086 | ||
| 005 | 20251231103633.0 | ||
| 024 | 7 | _ | |a 10.1002/alz70861_108043 |2 doi |
| 024 | 7 | _ | |a 1552-5260 |2 ISSN |
| 024 | 7 | _ | |a 1552-5279 |2 ISSN |
| 037 | _ | _ | |a DZNE-2025-01493 |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Göschel, Laura |b 0 |
| 111 | 2 | _ | |a Alzheimer’s Association International Conference |g AAIC 25 |c Toronto |d 2025-07-27 - 2025-07-31 |w Canada |
| 245 | _ | _ | |a 7T MRS Glutamate and GABA in Alzheimer’s Disease |
| 260 | _ | _ | |c 2025 |
| 336 | 7 | _ | |a Abstract |b abstract |m abstract |0 PUB:(DE-HGF)1 |s 1767100399_6286 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a Conference Paper |0 33 |2 EndNote |
| 336 | 7 | _ | |a INPROCEEDINGS |2 BibTeX |
| 336 | 7 | _ | |a conferenceObject |2 DRIVER |
| 336 | 7 | _ | |a Journal Article |0 PUB:(DE-HGF)16 |2 PUB:(DE-HGF) |m journal |
| 336 | 7 | _ | |a Output Types/Conference Abstract |2 DataCite |
| 336 | 7 | _ | |a OTHER |2 ORCID |
| 520 | _ | _ | |a Background:Functional neuroimaging studies suggest a dynamic trajectory in Alzheimer’s disease (AD), with early hyperconnectivity followed by hypoconnectivity due to pathologic progression. This study aimed to investigate this hypothesis using neurochemical markers derived from high-field magnetic resonance spectroscopy (MRS).Method:We analyzed data from 126 older adults enrolled in the NeuroMET studies, spanning from normal aging to dementia due to suspected AD. Using ultra-high-field 7 Tesla MRS, we quantified levels of the neurotransmitters glutamate (excitatory) and GABA (inhibitory) in the precentral cortex. Plasma p -Tau181 was used as a proxy for AD pathology, and memory was assessed using the NeuroMET Memory Metric (NMM). A p -Tau181 threshold of >2.08 pg/mL was applied as an estimated marker of amyloid positivity (Aß+). Linear mixed-effects models, adjusted for age at baseline, were used to evaluate associations and interaction effects.Result:Glutamate levels showed a non-linear association with age, decreasing up to around 70 years and increasing thereafter, while GABA levels remained stable (Figure 1A–C). Before reaching the suggested pathological conversion threshold for amyloid positivity, both glutamate and GABA showed a slight, non-significant increase in individuals with higher p -Tau181 levels (Figure 1D–F). Notably, amyloid status moderated the relationship between memory ability and glutamate levels (Figure 1G–I). Among Aß-negative individuals, lower memory ability was associated with elevated glutamate, potentially reflecting a very early compensatory response.Conclusion:Our findings support the hypothesis of a non-linear neurochemical trajectory in aging and early AD pathology. The observed age-dependent fluctuations in glutamate, together with subtle shifts in response to rising plasma p -Tau181, may reflect early pathologic or compensatory mechanisms. The interaction between glutamate and memory ability, particularly in supposedly Aß-negative individuals, suggests that excitatory neurotransmission could transiently support cognitive function in the face of emerging pathology. Notably, the threshold of plasma p -Tau181 used to define amyloid positivity may identify individuals in progressed stages, potentially missing earlier windows of therapeutic opportunity. As potential treatments may have markedly different effects depending on the stage of disease progression, investigating the trajectory of neuronal connectivity and activity is critical. |
| 536 | _ | _ | |a 353 - Clinical and Health Care Research (POF4-353) |0 G:(DE-HGF)POF4-353 |c POF4-353 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, Journals: pub.dzne.de |
| 700 | 1 | _ | |a Dell Orco, Andrea |0 P:(DE-2719)9001684 |b 1 |u dzne |
| 700 | 1 | _ | |a Ittermann, Bernd |b 2 |
| 700 | 1 | _ | |a Teunissen, Charlotte E. |b 3 |
| 700 | 1 | _ | |a Hoede, Patty |b 4 |
| 700 | 1 | _ | |a Melin, Jeanette |b 5 |
| 700 | 1 | _ | |a Pendrill, Leslie |b 6 |
| 700 | 1 | _ | |a Roemer-Cassiano, Sebastian |b 7 |
| 700 | 1 | _ | |a Franzmeier, Nicolai |b 8 |
| 700 | 1 | _ | |a Körtvelyessy, Peter |0 P:(DE-2719)2812030 |b 9 |u dzne |
| 700 | 1 | _ | |a Flöel, Agnes |0 P:(DE-2719)2812683 |b 10 |u dzne |
| 700 | 1 | _ | |a Fillmer, Ariane |b 11 |
| 773 | _ | _ | |a 10.1002/alz70861_108043 |g Vol. 21, no. S7, p. e108043 |0 PERI:(DE-600)2201940-6 |n S7 |p e108043 |t Alzheimer's and dementia |v 21 |y 2025 |x 1552-5260 |
| 856 | 4 | _ | |y OpenAccess |u https://pub.dzne.de/record/283086/files/DZNE-2025-1493.pdf |
| 856 | 4 | _ | |y OpenAccess |x pdfa |u https://pub.dzne.de/record/283086/files/DZNE-2025-1493.pdf?subformat=pdfa |
| 909 | C | O | |o oai:pub.dzne.de:283086 |p openaire |p open_access |p VDB |p driver |p dnbdelivery |
| 910 | 1 | _ | |a External Institute |0 I:(DE-HGF)0 |k Extern |b 1 |6 P:(DE-2719)9001684 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 9 |6 P:(DE-2719)2812030 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 10 |6 P:(DE-2719)2812683 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Neurodegenerative Diseases |1 G:(DE-HGF)POF4-350 |0 G:(DE-HGF)POF4-353 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Clinical and Health Care Research |x 0 |
| 914 | 1 | _ | |y 2025 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2025-01-06 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2025-01-06 |
| 915 | _ | _ | |a Creative Commons Attribution CC BY 4.0 |0 LIC:(DE-HGF)CCBY4 |2 HGFVOC |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b ALZHEIMERS DEMENT : 2022 |d 2025-01-06 |
| 915 | _ | _ | |a DEAL Wiley |0 StatID:(DE-HGF)3001 |2 StatID |d 2025-01-06 |w ger |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2025-01-06 |
| 915 | _ | _ | |a IF >= 10 |0 StatID:(DE-HGF)9910 |2 StatID |b ALZHEIMERS DEMENT : 2022 |d 2025-01-06 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2025-01-06 |
| 915 | _ | _ | |a OpenAccess |0 StatID:(DE-HGF)0510 |2 StatID |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2025-01-06 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2025-01-06 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2025-01-06 |
| 920 | 1 | _ | |0 I:(DE-2719)5000006 |k AG Düzel |l Clinical Neurophysiology and Memory |x 0 |
| 920 | 1 | _ | |0 I:(DE-2719)5000081 |k AG Flöel |l Dementia Prevention – Mechanisms and Clinical Implementation |x 1 |
| 980 | _ | _ | |a abstract |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a UNRESTRICTED |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a I:(DE-2719)5000006 |
| 980 | _ | _ | |a I:(DE-2719)5000081 |
| 980 | 1 | _ | |a FullTexts |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|